Single-cycle adenovirus vectors in the current vaccine landscape
Introduction: Traditional inactivated and protein vaccines generate strong antibodies, but struggle to generate T cell responses. Attenuated pathogen vaccines generate both, but risk causing the disease they aim to prevent. Newer gene-based vaccines drive both responses and avoid the risk of infecti...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2018-02-01
|
| Series: | Expert Review of Vaccines |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/14760584.2018.1419067 |
| _version_ | 1797680411590000640 |
|---|---|
| author | Michael Barry |
| author_facet | Michael Barry |
| author_sort | Michael Barry |
| collection | DOAJ |
| description | Introduction: Traditional inactivated and protein vaccines generate strong antibodies, but struggle to generate T cell responses. Attenuated pathogen vaccines generate both, but risk causing the disease they aim to prevent. Newer gene-based vaccines drive both responses and avoid the risk of infection. While these replication-defective (RD) vaccines work well in small animals, they can be weak in humans because they do not replicate antigen genes like more potent replication-competent (RC) vaccines. RC vaccines generate substantially stronger immune responses, but also risk causing their own infections. To circumvent these problems, we developed single-cycle adenovirus (SC-Ad) vectors that amplify vaccine genes, but that avoid the risk of infection. This review will discuss these vectors and their prospects for use as vaccines. Areas covered: This review provides a background of different types of vaccines. The benefits of gene-based vaccines and their ability to replicate antigen genes are described. Adenovirus vectors are discussed and compared to other vaccine types. Replication-defective, single-cycle, and replication-competent Ad vaccines are compared. Expert commentary: The potential utility of these vaccines are discussed when used against infectious diseases and as cancer vaccines. We propose a move away from replication-defective vaccines towards more robust replication-competent or single-cycle vaccines. |
| first_indexed | 2024-03-11T23:29:38Z |
| format | Article |
| id | doaj.art-473d6ed151e148cf82151f34a0aeb838 |
| institution | Directory Open Access Journal |
| issn | 1476-0584 1744-8395 |
| language | English |
| last_indexed | 2024-03-11T23:29:38Z |
| publishDate | 2018-02-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Expert Review of Vaccines |
| spelling | doaj.art-473d6ed151e148cf82151f34a0aeb8382023-09-20T10:18:03ZengTaylor & Francis GroupExpert Review of Vaccines1476-05841744-83952018-02-0117216317310.1080/14760584.2018.14190671419067Single-cycle adenovirus vectors in the current vaccine landscapeMichael Barry0Mayo ClinicIntroduction: Traditional inactivated and protein vaccines generate strong antibodies, but struggle to generate T cell responses. Attenuated pathogen vaccines generate both, but risk causing the disease they aim to prevent. Newer gene-based vaccines drive both responses and avoid the risk of infection. While these replication-defective (RD) vaccines work well in small animals, they can be weak in humans because they do not replicate antigen genes like more potent replication-competent (RC) vaccines. RC vaccines generate substantially stronger immune responses, but also risk causing their own infections. To circumvent these problems, we developed single-cycle adenovirus (SC-Ad) vectors that amplify vaccine genes, but that avoid the risk of infection. This review will discuss these vectors and their prospects for use as vaccines. Areas covered: This review provides a background of different types of vaccines. The benefits of gene-based vaccines and their ability to replicate antigen genes are described. Adenovirus vectors are discussed and compared to other vaccine types. Replication-defective, single-cycle, and replication-competent Ad vaccines are compared. Expert commentary: The potential utility of these vaccines are discussed when used against infectious diseases and as cancer vaccines. We propose a move away from replication-defective vaccines towards more robust replication-competent or single-cycle vaccines.http://dx.doi.org/10.1080/14760584.2018.1419067vaccinesgene-based vaccinesadenovirusreplicating |
| spellingShingle | Michael Barry Single-cycle adenovirus vectors in the current vaccine landscape Expert Review of Vaccines vaccines gene-based vaccines adenovirus replicating |
| title | Single-cycle adenovirus vectors in the current vaccine landscape |
| title_full | Single-cycle adenovirus vectors in the current vaccine landscape |
| title_fullStr | Single-cycle adenovirus vectors in the current vaccine landscape |
| title_full_unstemmed | Single-cycle adenovirus vectors in the current vaccine landscape |
| title_short | Single-cycle adenovirus vectors in the current vaccine landscape |
| title_sort | single cycle adenovirus vectors in the current vaccine landscape |
| topic | vaccines gene-based vaccines adenovirus replicating |
| url | http://dx.doi.org/10.1080/14760584.2018.1419067 |
| work_keys_str_mv | AT michaelbarry singlecycleadenovirusvectorsinthecurrentvaccinelandscape |